Journal Article
. 1993 Jan; 29A(3):319-24.
doi: 10.1016/0959-8049(93)90376-q.

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

V Trillet-Lenoir 1 J Green  C Manegold  J Von Pawel  U Gatzemeier  B Lebeau  A Depierre  P Johnson  G Decoster  D Tomita  
  • PMID: 7691119
  •     92 citations


The aim of this study was to determine the usefulness of recombinant human granulocyte colony stimulating factor (r-metHuG-CSF) following conventional chemotherapy for small cell lung cancer. 130 previously untreated patients were randomised to receive either r-metHuG-CSF (230 micrograms/m2) or placebo on days 4-17 following CDE (cyclophosphamide, doxorubicin and etoposide) chemotherapy. Over all cycles, 53% of 64 patients on placebo and only 26% of 65 patients on r-metHuG-CSF had at least one experience of neutropenia with fever defined as a neutrophil count less than 1.0 x 10(9)/l and a temperature > or = 38.2 degrees C (P < 0.002). It resulted in a reduction in the requirement for parenteral antibiotics from 58% in placebo patients compared with 37% in the r-metHuG-CSF group (P < 0.02), and a significant reduction in the incidence of infection-related hospitalisation. Chemotherapy doses were reduced by 15% or more at least once in 61% of the placebo group compared with 29% in the r-metHuG-CSF group (P < 0.001). 47% of the patients treated with placebo and 29% of the patients treated with r-metHuG-CSF experienced at least one cycle with a delay of 2 days or more in the administration of chemotherapy (P < 0.04). r-metHuG-CSF was well tolerated. There were no significant differences between the two groups in terms of response or survival.

The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study.
A Di Leo, E Bajetta, +7 authors, F Raspagliesi.
Br J Cancer, 1994 May 01; 69(5). PMID: 7514030    Free PMC article.
Recombinant methionyl granulocyte colony-stimulating factor (filgrastim): a new dimension in immunotherapy.
G Schwab, T Hecht.
Ann Hematol, 1994 Jul 01; 69(1). PMID: 7520285
Erysipelas in neutropenia of unknown origin, successfully treated with r-metHuG-CSF (filgrastim)
M Müller-Lühr, N Breyer, A Martin, H Haacke.
Ann Hematol, 1994 Aug 01; 69(2). PMID: 7521672
Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.
J E Frampton, C R Lee, D Faulds.
Drugs, 1994 Nov 01; 48(5). PMID: 7530630
Interventional antimicrobial therapy in febrile neutropenic patients. Study Group of the Paul Ehrlich Society for Chemotherapy.
H Link, G Maschmeyer, +4 authors, D Adam.
Ann Hematol, 1994 Nov 01; 69(5). PMID: 7948312
Cytokines in Hematology, Oncology, and Immunology. 3rd International Symposium. Hannover, June 23-26, 1993. Abstracts.
Ann Hematol, 1993 Jun 01; 66(6). PMID: 8100451    Free PMC article.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer.
A Ardizzoni, M Venturini, +7 authors, P Queirolo.
Br J Cancer, 1994 Feb 01; 69(2). PMID: 8297739    Free PMC article.
Aging and haemopoiesis. Implications for treatment with haemopoietic growth factors.
G S Chatta, D C Dale.
Drugs Aging, 1996 Jul 01; 9(1). PMID: 8818584
Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer.
A Ardizzoni, M C Pennucci, +7 authors, R Rosso.
Br J Cancer, 1996 Oct 01; 74(7). PMID: 8855989    Free PMC article.
Sertraline-induced agranulocytosis.
C Trescoli-Serrano, N K Smith.
Postgrad Med J, 1996 Jul 01; 72(849). PMID: 8935613    Free PMC article.
CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.
M Fukuoka, N Masuda, +10 authors, K Furuse.
Br J Cancer, 1997 Jan 01; 75(2). PMID: 9010043    Free PMC article.
Hematopoietic growth factors in cancer patients with invasive fungal infections.
F Offner.
Eur J Clin Microbiol Infect Dis, 1997 Jan 01; 16(1). PMID: 9063675
[G-CSF in radiochemotherapy].
M Riepl, R Fietkau, R Sauer.
Strahlenther Onkol, 1997 Feb 01; 173(2). PMID: 9072843
A comparative review of colony-stimulating factors.
J Nemunaitis.
Drugs, 1997 Nov 14; 54(5). PMID: 9360058
The discovery, development and clinical applications of granulocyte colony-stimulating factor.
D C Dale.
Trans Am Clin Climatol Assoc, 1998 May 28; 109. PMID: 9601125    Free PMC article.
Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia.
J E Frampton, D Faulds.
Pharmacoeconomics, 1995 Dec 09; 9(1). PMID: 10161371
Impact of ASCO guidelines for the use of hematopoietic colony stimulating factors (CSFs): survey results of fifteen Paris university hospitals.
I Debrix, I Madelaine, +7 authors, P Tilleul.
Pharm World Sci, 2000 Feb 05; 21(6). PMID: 10658236
Haemopoietic growth factors in paediatric oncology: a review of the literature.
L M Wagner, W L Furman.
Paediatr Drugs, 2001 Apr 20; 3(3). PMID: 11310717
A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics.
J P Sculier, M Paesmans, +13 authors, European Lung Cancer Working Party.
Br J Cancer, 2001 Nov 27; 85(10). PMID: 11720426    Free PMC article.
Economic analysis of filgrastim use for patients with acute myeloid leukaemia in the UK: a comparison of collection methods of resource use data.
Bo Standaert, Janet Goldstone, +2 authors, John Liu Yin.
Pharmacoeconomics, 2002 Aug 07; 20(10). PMID: 12162755
Colony-stimulating factors for the management of neutropenia in cancer patients.
David C Dale.
Drugs, 2002 Dec 14; 62 Suppl 1. PMID: 12479591
Treatment of breast cancer with chemotherapy in combination with filgrastim: approaches to improving therapeutic outcome.
Giuseppe Frasci.
Drugs, 2002 Dec 14; 62 Suppl 1. PMID: 12479592
Filgrastim in patients with neutropenia: potential effects on quality of life.
Gary H Lyman, Nicole M Kuderer.
Drugs, 2002 Dec 14; 62 Suppl 1. PMID: 12479595
Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
Jeffrey Crawford.
Drugs, 2002 Dec 14; 62 Suppl 1. PMID: 12479597
First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study.
Edgardo Rivera, M Haim Erder, +2 authors, Gabriel N Hortobagyi.
Breast Cancer Res, 2003 Aug 21; 5(5). PMID: 12927041    Free PMC article.
The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study.
Susan Haithcox, Carmella R Ramnes, +2 authors, Gary H Lyman.
BMC Nurs, 2003 Sep 23; 2(1). PMID: 14498996    Free PMC article.
A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia.
Y Lalami, M Paesmans, +5 authors, J Klastersky.
Support Care Cancer, 2004 Jul 06; 12(10). PMID: 15235901
Single infusion of myeloid progenitors reduces death from Aspergillus fumigatus following chemotherapy-induced neutropenia.
Andrew BitMansour, Thai M Cao, +2 authors, Janice M Y Brown.
Blood, 2004 Dec 04; 105(9). PMID: 15576478    Free PMC article.
Neoplastic fever: a neglected paraneoplastic syndrome.
Jason A Zell, Jae C Chang.
Support Care Cancer, 2005 May 03; 13(11). PMID: 15864658
Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : the 40% rule revisited.
Elizabeth A Calhoun, Glen T Schumock, +6 authors, Charles L Bennett.
Pharmacoeconomics, 2005 Aug 16; 23(8). PMID: 16097839
Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia.
César Gómez Raposo, Alvaro Pinto Marín, Manuel González Barón.
Clin Transl Oncol, 2006 Nov 01; 8(10). PMID: 17074671
Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer.
R Pirker, E Ulsperger, +5 authors, T Skacel.
Lung, 2007 Jan 20; 184(5). PMID: 17235728
Modern management of small-cell lung cancer.
Roberta Ferraldeschi, Sofia Baka, +3 authors, Paul Lorigan.
Drugs, 2007 Oct 12; 67(15). PMID: 17927281
Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.
D Almenar, J Mayans, +8 authors, J Sanchez.
Eur J Cancer Care (Engl), 2008 Dec 17; 18(3). PMID: 19076208    Free PMC article.
Effects of recombinant human granulocyte colony-stimulating factor (filgrastim) on ECG parameters in neutropenic patients: a single-centre, prospective study.
Ozlem Guneysel, Ozge Ecmel Onur, Arzu Denizbasi.
Clin Drug Investig, 2009 Jul 14; 29(8). PMID: 19591516
Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen.
Rodolfo Mattioli, Cesare Gridelli, +7 authors, Ana Casas.
Clin Transl Oncol, 2010 Jan 05; 11(12). PMID: 20045791
Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients.
Sheri L Spunt, Helen Irving, +5 authors, Victor M Santana.
J Clin Oncol, 2010 Feb 10; 28(8). PMID: 20142595    Free PMC article.
Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
Matti Aapro, Jeffrey Crawford, Didier Kamioner.
Support Care Cancer, 2010 Mar 02; 18(5). PMID: 20191292    Free PMC article.
The colony-stimulating factors and cancer.
Donald Metcalf.
Nat Rev Cancer, 2010 May 25; 10(6). PMID: 20495576    Free PMC article.
Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies.
Howard A Burris, Chandra P Belani, +6 authors, Alan Saven.
J Oncol Pract, 2010 Sep 03; 6(3). PMID: 20808556    Free PMC article.
Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.
Katy L Cooper, Jason Madan, +2 authors, Ron L Akehurst.
BMC Cancer, 2011 Sep 29; 11. PMID: 21943360    Free PMC article.
Systematic Review.
Re: personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.
Arnold L Potosky, Jennifer L Malin, +2 authors, Jane C Weeks.
J Natl Cancer Inst, 2011 Nov 01; 103(24). PMID: 22036767    Free PMC article.
A way forward on the medically appropriate use of white cell growth factors.
Thomas J Smith, Bruce E Hillner.
J Clin Oncol, 2012 Mar 01; 30(14). PMID: 22370327    Free PMC article.
Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.
Bradford R Hirsch, Gary H Lyman.
Pharmacoeconomics, 2012 May 01; 30(6). PMID: 22540394
Systematic Review.
Management of neutropenia in cancer patients.
Maryam B Lustberg.
Clin Adv Hematol Oncol, 2012 Dec 29; 10(12). PMID: 23271355    Free PMC article.
Supportive therapy in medical therapy of head and neck tumors.
Hartmut Link.
GMS Curr Top Otorhinolaryngol Head Neck Surg, 2013 Jan 16; 11. PMID: 23320053    Free PMC article.
Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia.
A K Altwairgi, W M Hopman, M Mates.
Curr Oncol, 2013 Jun 06; 20(3). PMID: 23737687    Free PMC article.
Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy.
Igor Bondarenko, Oleg A Gladkov, +2 authors, Peter Bias.
BMC Cancer, 2013 Aug 16; 13. PMID: 23945072    Free PMC article.
Cataract associated with high-dose hematopoietic colony stimulating factor, case report and literature review.
Soad K Aljaouni, Hanadi M Aljedani.
Saudi Pharm J, 2010 Apr 01; 18(2). PMID: 23960727    Free PMC article.
Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.
Didier Kamioner, Stefan Fruehauf, +3 authors, Christian Berthou.
BMC Cancer, 2013 Nov 19; 13. PMID: 24237790    Free PMC article.
Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study.
Luigi Rossi, Federica Tomao, +10 authors, Silverio Tomao.
Ther Clin Risk Manag, 2013 Nov 21; 9. PMID: 24255599    Free PMC article.
A prospective observational study to evaluate G-CSF usage in patients with solid tumors receiving myelosuppressive chemotherapy in Italian clinical oncology practice.
S Barni, V Lorusso, +10 authors, P Pronzato.
Med Oncol, 2013 Dec 07; 31(1). PMID: 24307348
Severe neutropenia and relative dose intensity among patients<65 and ≥65 years with non-Hodgkin's lymphoma receiving CHOP-based chemotherapy.
Lee S Schwartzberg, Mansoor Saleh, Sadie Whittaker, Esteban Abella.
Support Care Cancer, 2014 Feb 19; 22(7). PMID: 24535242
Granulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.
Sol Cortés de Miguel, Miguel Ángel Calleja-Hernández, Salomón Menjón-Beltrán, Inmaculada Vallejo-Rodríguez.
Support Care Cancer, 2014 Oct 07; 23(2). PMID: 25284722
The effect of granulocyte-colony stimulating factor on rotator cuff healing after injury and repair.
David Ross, Tristan Maerz, +5 authors, Kevin Baker.
Clin Orthop Relat Res, 2015 Mar 04; 473(5). PMID: 25733010    Free PMC article.
The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
Li Wang, Onur Baser, +2 authors, Richard Barron.
Support Care Cancer, 2015 Mar 31; 23(11). PMID: 25821144    Free PMC article.
Systematic Review.
Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.
Oleg Gladkov, Vladimir Moiseyenko, +5 authors, Noa Avisar.
Med Oncol, 2015 May 15; 32(6). PMID: 25966791
Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating Factor.
Tara Arvedson, James O'Kelly, Bing-Bing Yang.
BioDrugs, 2015 May 23; 29(3). PMID: 25998211    Free PMC article.
A thorough QT study to assess the effects of tbo-filgrastim on cardiac repolarization in healthy subjects.
Liat Adar, Noa Avisar, +2 authors, Ofer Spiegelstein.
Drug Des Devel Ther, 2015 Jun 02; 9. PMID: 26028962    Free PMC article.
G-CSF and GM-CSF in Neutropenia.
Hrishikesh M Mehta, Michael Malandra, Seth J Corey.
J Immunol, 2015 Aug 09; 195(4). PMID: 26254266    Free PMC article.
Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?
Derek Weycker, Xiaoyan Li, +3 authors, May Hagiwara.
Support Care Cancer, 2015 Nov 27; 24(5). PMID: 26607482    Free PMC article.
Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.
Ruth Pettengell, Peter Bias, Udo Mueller, Nicole Lang.
Support Care Cancer, 2016 Jan 19; 24(6). PMID: 26780505
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients.
Roberto Guariglia, Maria Carmen Martorelli, +3 authors, Pellegrino Musto.
Biologics, 2016 Feb 10; 10. PMID: 26858523    Free PMC article.
Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy.
Yanli Li, Zandra Klippel, +3 authors, John H Page.
Cancer Chemother Pharmacol, 2016 Feb 18; 77(4). PMID: 26886017    Free PMC article.
Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting.
Eiseki Usami, Michio Kimura, +3 authors, Tomoaki Yoshimura.
Mol Clin Oncol, 2016 Apr 14; 4(4). PMID: 27073670    Free PMC article.
Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies.
Yanli Li, Zandra Klippel, +3 authors, John H Page.
Support Care Cancer, 2016 Jun 10; 24(10). PMID: 27278272
Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.
Derek Weycker, Xiaoyan Li, +5 authors, Gary H Lyman.
Support Care Cancer, 2016 Oct 14; 25(2). PMID: 27734153
Am80-GCSF synergizes myeloid expansion and differentiation to generate functional neutrophils that reduce neutropenia-associated infection and mortality.
Lin Li, Xiaotian Qi, +12 authors, Lingtao Wu.
EMBO Mol Med, 2016 Nov 04; 8(11). PMID: 27737899    Free PMC article.
Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.
Stefan Fruehauf, Burkhard Otremba, Oliver Stötzer, Christine Rudolph.
Adv Ther, 2016 Oct 28; 33(11). PMID: 27743353    Free PMC article.
Towards Quantitative Systems Pharmacology Models of Chemotherapy-Induced Neutropenia.
M Craig.
CPT Pharmacometrics Syst Pharmacol, 2017 Apr 19; 6(5). PMID: 28418603    Free PMC article.
Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
T Christopher Bond, Erika Szabo, +5 authors, Boxiong Tang.
J Oncol Pharm Pract, 2017 Jun 16; 24(6). PMID: 28614980    Free PMC article.
A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.
David C Dale, Jeffrey Crawford, +6 authors, Gary H Lyman.
Support Care Cancer, 2017 Sep 25; 26(1). PMID: 28939926    Free PMC article.
Systematic Review.
Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer.
Esse I H Akpo, Irshaad R Jansen, Edith Maes, Steven Simoens.
Front Pharmacol, 2017 Sep 29; 8. PMID: 28955224    Free PMC article.
Effectiveness and Safety of Pegfilgrastim in BEP Treatment for Patients with Germ Cell Tumor.
Hiroaki Iwamoto, Kouji Izumi, +5 authors, Atsushi Mizokami.
In Vivo, 2018 Jun 25; 32(4). PMID: 29936477    Free PMC article.
Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia.
Burkhard Otremba, Carsten Hielscher, Volker Petersen, Christian Petrik.
Patient Prefer Adherence, 2018 Nov 10; 12. PMID: 30410313    Free PMC article.
Filgrastim prophylaxis in elderly cancer patients in the real-life setting: a French multicenter observational study, the TULIP study.
Kamel Laribi, Delphine Badinand, +5 authors, Rafik Diab.
Support Care Cancer, 2019 Mar 16; 27(11). PMID: 30874925    Free PMC article.
Strategies to generate functionally normal neutrophils to reduce infection and infection-related mortality in cancer chemotherapy.
Hisham Abdel-Azim, Weili Sun, Lingtao Wu.
Pharmacol Ther, 2019 Aug 31; 204. PMID: 31470030    Free PMC article.
Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network meta-analysis.
Yong Wang, Lin Chen, +4 authors, Yong Li.
Sci Rep, 2019 Oct 28; 9(1). PMID: 31653961    Free PMC article.
Systematic Review.
Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.
Gregory S Calip, Kellyn M Moran, +7 authors, Brian C-H Chiu.
Cancer, 2018 Dec 15; 125(7). PMID: 30548485    Free PMC article.
Review of oncological emergencies in small animal patients.
Katrina L Tumielewicz, Danielle Hudak, +2 authors, Lisa A Murphy.
Vet Med Sci, 2019 Mar 23; 5(3). PMID: 30900396    Free PMC article.
Efficacy of Jackfruit365™ Green Jackfruit Flour Fortified Diet on Pegfilgrastim to Prevent Chemotherapy-Induced Leukopenia, Irrespective of Tumor Type or Drugs Used-A Retrospective Study.
Thomas Varughese, James Joseph, Rejeesh Menon.
Biomolecules, 2020 Feb 07; 10(2). PMID: 32024271    Free PMC article.
Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
Julia Bohlius, Christine Herbst, +2 authors, Andreas Engert.
Cochrane Database Syst Rev, 2008 Oct 10; (4). PMID: 18843642    Free PMC article.
Systematic Review.
A Novel Paradigm Between Leukocytosis, G-CSF Secretion, Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer.
Montreh Tavakkoli, Cy R Wilkins, Jodi V Mones, Michael J Mauro.
Front Oncol, 2019 May 14; 9. PMID: 31080780    Free PMC article.
Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
Nicole Skoetz, Julia Bohlius, +3 authors, Jörg-Janne Vehreschild.
Cochrane Database Syst Rev, 2015 Dec 22; (12). PMID: 26687844    Free PMC article.
Systematic Review.
Predicting neutropenia risk in patients with cancer using electronic data.
Pamala A Pawloski, Avis J Thomas, +3 authors, Gary H Lyman.
J Am Med Inform Assoc, 2016 Sep 18; 24(e1). PMID: 27638907    Free PMC article.
Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice.
Ahuva Averin, Amanda Silvia, +8 authors, Derek Weycker.
Support Care Cancer, 2020 Sep 04; 29(4). PMID: 32880732    Free PMC article.
Randomized and dose-escalation trials of recombinant human serum albumin /granulocyte colony-stimulating factor in patients with breast cancer receiving anthracycline-containing chemotherapy.
Shanshan Chen, Yiqun Han, +15 authors, Binghe Xu.
BMC Cancer, 2021 Apr 02; 21(1). PMID: 33789616    Free PMC article.
Development and Internal Validation of a Nomogram Used to Predict Chemotherapy-Induced Neutropenia in Non-Small Cell Lung Cancer Patients: A Retrospective Cohort Study.
Wei Zou, Neng-Luan Xu.
Cancer Manag Res, 2021 Apr 06; 13. PMID: 33814928    Free PMC article.
G-CSF in tumors: Aggressiveness, tumor microenvironment and immune cell regulation.
Ioannis Karagiannidis, Eralda Salataj, Erika Said Abu Egal, Ellen J Beswick.
Cytokine, 2021 Mar 08; 142. PMID: 33677228    Free PMC article.
A retrospective analysis of nadir-neutropenia directed pegylated granulocyte-colony stimulating factor on febrile neutropenia rates in (neo)adjuvant breast cancer chemotherapy regimens.
Sarah J Zardawi, Ina Nordman, Nicholas Zdenkowski.
Cancer Rep (Hoboken), 2020 Aug 08; 3(5). PMID: 32761893    Free PMC article.
Preclinical immunogenicity testing using anti-drug antibody analysis of GX-G3, Fc-fused recombinant human granulocyte colony-stimulating factor, in rat and monkey models.
Yun Jung Kim, Eun Mi Koh, +7 authors, Kyung Jin Jung.
Sci Rep, 2021 Jun 09; 11(1). PMID: 34099775    Free PMC article.
Pooled Analysis on the Effectiveness and Safety of Lipegfilgrastim in Patients With Urological Malignancies in the Real-World Setting.
Axel S Merseburger, Götz Geiges, +2 authors, Petra Pichler.
Front Oncol, 2021 Jun 15; 11. PMID: 34123810    Free PMC article.
Systematic Review.